Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Tareq Abuasab(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Caitlin R. Rausch(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Rabiul Islam(The University of Texas MD Anderson Cancer Center), Kathryn Montalbano(The University of Texas MD Anderson Cancer Center)
Cited by 25
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k